SCHEMBL29628508

SCHEMBL29628508

C=Cc1cc(C(F)(F)F)c(Cl)cn1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 8/20 0.34
TEK Q02763 1/20 0.33
S1PR4 O95977 1/20 0.32
PIK3CD O00329 1/20 0.32
LMNA P02545 1/20 0.31
COMT P21964 1/20 0.31
IDO1 P14902 1/20 0.31
HTR3E A5X5Y0 1/20 0.31
HTR3B O95264 1/20 0.31
HTR3A P46098 1/20 0.31
HTR3D Q70Z44 1/20 0.31
HTR3C Q8WXA8 1/20 0.31
KDR P35968 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GRM4 Q14833 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628442 0.79 BTK (0.31)
SCHEMBL29628445 0.76 S1PR4 (0.33) S1PR4ALDH1A1
SCHEMBL12301889 0.75 CD44 (0.32) S1PR4ALDH1A1
SCHEMBL29435663 0.74 PIK3R1 (0.41) NOTUMPIK3CDCOMTIDO1HTR3E
SCHEMBL1515470 0.74 PIK3R1 (0.41) NOTUMPIK3CDCOMTIDO1HTR3E
SCHEMBL26081130 0.74 CNR2 (0.32) NOTUM
SCHEMBL875844 0.73 CDK8 (0.46) NOTUMIDO1KDR
SCHEMBL19229213 0.73 ASPH (0.49) NOTUMALDH1A1
SCHEMBL13274209 0.72 COMT (0.40) NOTUMPIK3CDCOMTIDO1HTR3E
SCHEMBL4372965 0.71 PIK3CD (0.38) NOTUMPIK3CDCOMTIDO1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094935-A Amide prodrugs and uses thereof 2026-05-26 CN disclosed
WO-2025049767-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
CN-116134018-A 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor 默沙东有限责任公司 2023-05-16 CN disclosed
EP-3997096-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2022-05-18 EP disclosed